Company Overview

Inventiva S.A. is a clinical-stage biopharmaceutical company focused on the development of small-molecule therapies for the treatment of diseases with significant unmet medical need, particularly metabolic-associated steatohepatitis (MASH/NASH) and other fibrotic and inflammatory conditions. The company operates within the biotechnology and pharmaceutical research industry, with its value creation primarily driven by drug discovery and clinical development rather than commercialized products.

The company’s core asset is lanifibranor, a pan-PPAR agonist being developed as a potential first-in-class oral therapy for MASH/NASH. Inventiva was founded in 2011 and is headquartered in France, emerging from academic research and industry expertise in nuclear receptor biology. Since its inception, the company has transitioned from early discovery programs to late-stage clinical development, positioning itself as a specialized player in metabolic and fibrotic disease therapeutics.

Business Operations

Inventiva’s operations are centered on research and development, with activities spanning target identification, preclinical research, and clinical trials. The company’s primary business segment is clinical drug development, with expenditures largely allocated to clinical trials, regulatory interactions, and supporting scientific infrastructure. Inventiva does not currently generate recurring commercial revenue and relies on equity financing, collaborations, and grants to fund operations.

The company conducts clinical trials internationally while maintaining internal research capabilities in France. Its asset portfolio has historically included multiple preclinical programs, though current operations are highly concentrated on advancing lanifibranor through late-stage clinical evaluation. Inventiva has engaged in strategic collaborations in the past, including research partnerships with large pharmaceutical companies, though it currently operates independently without an active commercial joint venture for its lead asset.

Strategic Position & Investments

Inventiva’s strategic direction is focused on advancing lanifibranor through late-stage clinical development for MASH/NASH, a disease area with limited approved therapeutic options and significant global prevalence. The company’s strategy emphasizes differentiation through a pan-PPAR mechanism of action, which targets metabolic dysfunction, inflammation, and fibrosis simultaneously. This positioning is intended to address multiple underlying drivers of disease progression.

Investment activity is primarily internal, directed toward clinical trial execution, regulatory preparedness, and potential lifecycle expansion of lanifibranor into additional fibrotic or metabolic indications. Inventiva has also explored earlier-stage research programs, though these are not currently the primary strategic focus. No material acquisitions have been publicly confirmed in recent periods based on available disclosures.

Geographic Footprint

Inventiva is headquartered in France, with its principal offices and research operations located in Dijon. While its corporate footprint is concentrated in Europe, the company maintains a global operational reach through the execution of multinational clinical trials, particularly in North America, Europe, and other regions participating in late-stage MASH/NASH studies.

The company’s securities are publicly listed on Euronext Paris and trade in the United States via the OTC market, providing access to international investors. Inventiva does not maintain large-scale commercial operations or manufacturing facilities outside Europe, reflecting its current pre-commercial development stage.

Leadership & Governance

Inventiva is led by an executive team with experience in pharmaceutical research, clinical development, and corporate management. The leadership emphasizes a science-driven strategy focused on disciplined clinical execution and long-term value creation through innovation in metabolic disease therapeutics. Governance is overseen by a board of directors with industry and financial expertise.

Key executives include:

• Frédéric Cren – Chief Executive Officer and Co‑founder
• Pierre Broqua – Chief Scientific Officer and Co‑founder
• Stéphane Bonnefoy – Chief Financial Officer
• Colin Kay – Chairman of the Board
• Andrew Cheng – Independent Director and Clinical Development Advisor

The leadership team’s strategic vision centers on advancing Inventiva’s lead program toward regulatory approval while maintaining scientific rigor and financial discipline.